Apolipoprotein E modifies the CNS response to injury via a histamine-mediated pathway

REFERENCES

• Mahley RW. apol ipoproteinE: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622–630
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Sheng H, Bart RD, etal. Apolipoprotein [-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 1997; 17: 753–758
   PubMed Web of Science ®Google Scholar
• Sheng H, Laskowitz DT, Mackensen GB, et al. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke 1999; 30: 1118–1124
   PubMed Web of Science ®Google Scholar
• Chen Y, Lomnitski L, Michaelson DM, et al. Motor and cognitive deficits in apolipoprotein [-deficient mice after closed head injury. Neuroscience 1997; 80: 1255–1262
   PubMed Web of Science ®Google Scholar
• Lynch JR, Pineda JA, Morgan D, etal. Apolipoprotein [affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol 2002; 51: 113–117
   PubMed Web of Science ®Google Scholar
• Weisgraber KH. Apolipoprotein E: Structure—function relation-ships. Adv Protein Chem 1994; 45: 249–302
   PubMedGoogle Scholar
• Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein [type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921–923
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta- amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977–1981
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Graffagnino C, McClenny C, et al. Apo[ genotype and survival from intracerebral hemorrhage. Lancet 1995; 346: 575–579
   PubMed Web of Science ®Google Scholar
• Sorbi S, Nacmias B, Piacentini S, et al. Apo[ as a prognostic factor for post-traumatic coma. Nat Med 1995; 1: 852
   PubMed Web of Science ®Google Scholar
• Teasdale GM, Nicoll JA, Murray G, et al. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350: 1069–1071
   PubMed Web of Science ®Google Scholar
• Tardiff BE, Newman ME, Saunders AM, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. Ann Thorac Surg 1997; 64: 715–720
   PubMed Web of Science ®Google Scholar
• Sheng H, Laskowitz DT, Bennett E, et al. Apolipoprotein E isoformspecific differences in outcome from focal ischemia in transgenic mice. Cereb Blood Flow Metab 1998; 18: 361–366
   PubMed Web of Science ®Google Scholar
• Sabo T, Lomnitski L, Nyska A, et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 2000; 101: 879–884
   PubMed Web of Science ®Google Scholar
• Horsburgh K, McCulloch J, Nilsen M, et al. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischae-mia. Eur J Neurosci 2000; 12: 4309–4017
   PubMed Web of Science ®Google Scholar
• Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997; 388: 878–881
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Goel S, Bennett ER, et al. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 1997; 76: 70–74
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Thekdi AD, Thekdi SD, et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001; 167: 74–85
   PubMed Web of Science ®Google Scholar
• Lynch JR, Tang W, Wang H, etal. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003; 278: 48529–48533
   PubMed Web of Science ®Google Scholar
• Lynch JR, Morgan D, Mance J, et al. Apolipoprotein E modulates glial activation and endogenous central nervous system inflam-matory response. I Neuroimmunol 2001; 114: 107–113
   PubMed Web of Science ®Google Scholar
• Lynch JR, Wang H, Mace B, etal. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005; 192: 109–116
   PubMed Web of Science ®Google Scholar
• Hixson JE, Vernier DT. Restriction isotyping of human apolipo-protein E by gene amplification and cleavage with Hhal. I Lipid Res 1990; 31: 545–548
   PubMed Web of Science ®Google Scholar
• Kepler TB, Crosby L, Morgan KT. Normalization and analysis of DNA microarray data by self-consistency and local regression. Genome Biol 2002; 3: RESEARCH0037
   Google Scholar
• Uyttenhove C, Simpson RJ, Van Snick J. Functional and, structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988; 85: 6934–6938
   PubMed Web of Science ®Google Scholar
• Hamm RJ, Pike BR, O'Dell DM, et al. The rotarod test: An evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. I Neurotrauma 1994; 11: 187–196
   PubMed Web of Science ®Google Scholar
• Patkai J, Mesples B, Dommergues MA, et al. Deleterious effects of IL-9 activated mast cell and neuroprotection by antihistamine drugs in the developing mouse brain. Pediat Res 2001; 50: 222–230
   PubMed Web of Science ®Google Scholar
• Friedman G, Froom P, Sazbon L, etal. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999; 52: 244–248
   PubMed Web of Science ®Google Scholar
• Jordan BD, Relkin NR, Ravdin LD, etal. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997; 278: 136–140
   PubMed Web of Science ®Google Scholar
• Kutner KC, Erlanger DM, Tsai J, etal. Lower cognitive performance of older football players possessing apolipoprotein E epsilon4. Neurosurgery 2000; 47: 651–657
   PubMed Web of Science ®Google Scholar
• McCarron MO, Weir CJ, Muir KW, etal. Effect of apolipoprotein E genotype on in-hospital mortality following intracerebral haemor-rhage. Acta Neurol Scand 2003; 107: 106–109
   PubMed Web of Science ®Google Scholar
• Schiefermeier M, Kollegger H, Madl C, et al. Apolipoprotein E polymorphism: Survival and neurological outcome after cardio-pulmonary resuscitation. Stroke 2000; 31: 2068–2073
   PubMed Web of Science ®Google Scholar
• Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am] Hum Genet 2002; 70: 708–717
   PubMed Web of Science ®Google Scholar
• Demoulin JB, Renauld JC. Interleukin 9 and its receptor: An overview of structure and function. Int Rev Immunol 1998; 16: 345–364
   PubMedGoogle Scholar
• Dines KC, Powell HC. Mast cells interaction with the nervous system: Relationship to mechanism of disease. I Neuropathol Exp Neurol 1997; 56: 627–640
   PubMed Web of Science ®Google Scholar
• Sztriha L, Joo F, Szerdahelyi P. Histamine H2-receptors participate in the formation of brain edema induced by kainic acid in rat thalamus. Neurosci Lett 1987; 75: 334–338
   PubMed Web of Science ®Google Scholar
• Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523–530
   PubMed Web of Science ®Google Scholar
• Bart RD, Sheng H, Laskowitz DT, et al. Regional CBF in apolipoprotein [-deficient and wild type mice during focal cerebral ischemia. Neuroreport 1998; 9: 2615–2620
   PubMed Web of Science ®Google Scholar
• Knouff C, Hinsdale ME, Mezdour H, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. Clin Invest 1999; 130:1579–1586
   Google Scholar
• Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study. Neurology 2000; 54: 2066–2071
   PubMed Web of Science ®Google Scholar